Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Comment by Walterthedogon Jul 08, 2021 9:55am
175 Views
Post# 33511396

RE:RE:News and update

RE:RE:News and update Thats because it isn't good news. They are finally admitting that they are missing batch info and trial data. And at the rate they are doing source data verification, it should be next year instead of this summer that they can complete the phase 2. I strongly believe that they have known for some time that they can not complete the phase 2 without data that Aspire holds. Peter mentioned as much at the AGM. And how can you recreate trial data from site visits if you don't know who was treated with ACP or placebos? They pumped up the stock in December under the premise that they had recieved the trial data from Medrio when in fact they probably knew at the time that it was an incomplete data set. And ever since, they have strung along investors with increasingly longer timelines knowing full well that they can do nothing with their phase 2 trial unless they beat Aspire in court. So my conclusion is that they are basically pretending they can recreate the trial from site visits to show investors that A) they are working on it and B) they dont need to beat Aspire in court. I knew when they said 3 months for this process in April that it was a lie. Now they finally admit it will take longer but they aren't telling you that it is impossible without Aspires data and that they are simply stalling and hoping to win against Aspire next year sometime. This is just my best guess as to whats really going on but if you read between the lines, it makes sense. Smeenk is full of it and has been misleading investors for a long time. This is likely a lost cause and at the very least buckle up for another year of excuses and low priced desperate cash raises to pay lawyers. I hope im wrong but i haven't been thus far. My moneys basically gone so I'll just sit and watch this clown car show until it either miraculously works out or bursts into flame. Whichever comes first
<< Previous
Bullboard Posts
Next >>